Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ulixertinib (BVD-523)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BioMed Valley Discoveries

Drug class:

ERK2 inhibitor, ERK1 inhibitor

Related drugs:

BRAF L597Q	Solid Tumor	BRAF L597Q	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF G469A	Solid Tumor	BRAF G469A	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF G469V	Solid Tumor	BRAF G469V	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
BRAF L485W	Solid Tumor	BRAF L485W	Solid Tumor	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B	BVD-523 Sensitive: B - Late Trials BVD-523 Sensitive : B
NRAS mutation	Melanoma	NRAS mutation	Melanoma	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2
BRAF L485W	Gallbladder Cancer	BRAF L485W	Gallbladder Cancer	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
BRAF D594G	Melanoma	BRAF D594G	Melanoma	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
BRAF D594G	Colorectal Cancer	BRAF D594G	Colorectal Cancer	cetuximab + encorafenib + BVD-523 Sensitive: C3 – Early Trials cetuximab + encorafenib + BVD-523 Sensitive : C3	cetuximab + encorafenib + BVD-523 Sensitive: C3 – Early Trials cetuximab + encorafenib + BVD-523 Sensitive : C3
BRAF V600E	Glioblastoma	BRAF V600E	Glioblastoma	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
BRAF V600E	Pancreatic Ductal Adenocarcinoma	BRAF V600E	Pancreatic Ductal Adenocarcinoma	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
BRAF fusion	Glioma	BRAF fusion	Glioma	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
BRAF G469A	Head and Neck Cancer	BRAF G469A	Head and Neck Cancer	BVD-523 Sensitive: C4 – Case Studies BVD-523 Sensitive : C4	BVD-523 Sensitive: C4 – Case Studies BVD-523 Sensitive : C4
SPRED2 deletion	Estrogen Receptor Positive Breast Cancer	SPRED2 deletion	Estrogen Receptor Positive Breast Cancer	BVD-523 Sensitive: D – Preclinical BVD-523 Sensitive : D	BVD-523 Sensitive: D – Preclinical BVD-523 Sensitive : D
BRAF V600E	Glioma	BRAF V600E	Glioma	BVD-523 Sensitive: D – Preclinical BVD-523 Sensitive : D	BVD-523 Sensitive: D – Preclinical BVD-523 Sensitive : D
KIAA1549-BRAF fusion	Glioma	KIAA1549-BRAF fusion	Glioma	BVD-523 Sensitive: D – Preclinical BVD-523 Sensitive : D	BVD-523 Sensitive: D – Preclinical BVD-523 Sensitive : D